One Specification, Six Inventions: Continuation and Divisional Practice in the United States and China

Executive Summary   

 

This article explains how a single patent specification disclosing inventions A through F should be divided into later applications under U.S. and Chinese practice. In the United States, restricted inventions B and C should ordinarily be pursued in timely divisional applications to preserve the strongest protection under 35 U.S.C. § 121, while A3 and the previously unclaimed inventions D through F generally may be pursued in continuations under § 120 if the original disclosure provides adequate support and an unbroken copending chain is maintained. China, by contrast, offers no general continuation mechanism: commercially important subject matter must generally be placed in timely divisionals before expiration of the original application’s divisional window, and a pending divisional ordinarily does not extend that window except for a narrow examiner-driven lack-of-unity exception. The comparison demonstrates that coordinated portfolios should use deliberately different filing architectures in each jurisdiction rather than attempting to replicate U.S. continuation practice in China.

Introduction

 

A single patent specification may disclose far more than the claims pursued in the first application. That is common in platform technologies, product families, and research programs in which one disclosure describes a core concept, several distinct implementations, and additional inventions that may become commercially important later. The difficult question is not whether the specification contains the subject matter. It is how, and by when, the applicant must preserve the right to claim each invention.

Consider an application that discloses inventions A, B, C, D, E, and F. Invention A includes sub-inventions A1, A2, and A3. The application as filed contains claims directed to A, B, and C, but no claims directed to D, E, or F. The examiner imposes a restriction requirement among A, B, and C. The applicant elects A and cancels the claims to B and C. The examiner later allows claims that cover A1 and A2, but not A3.

The filing strategy that follows from those facts differs sharply between the United States and China. In the United States, a properly supported and continuously pending application chain can preserve substantial flexibility. B and C should ordinarily be pursued in divisionals tied to the restriction requirement; A3 ordinarily belongs in a continuation; and D through F may potentially be claimed in a continuation even though they were never claimed in the original application. In China, the practitioner should not assume that maintaining one divisional will keep every disclosed branch alive. China has no direct counterpart to the open-ended U.S. continuation. Its ordinary deadline for a voluntary divisional is generally measured from the first-filed Chinese application, and a pending divisional ordinarily does not restart that clock.

That contrast produces a useful planning maxim: in the United States, preserve a supported pending chain; in China, file every commercially important voluntary divisional before the first-filed application’s divisional window closes.

Key Terms Used in This Article

 

In U.S. practice, a continuation is a later application that seeks the benefit of an earlier nonprovisional application’s filing date while presenting claims to subject matter already disclosed there; a continuation-in-part adds subject matter not disclosed in the earlier application, so the earlier date benefits only claims adequately supported by the earlier disclosure. A divisional is a continuing application carved from an earlier application to pursue an independent or distinct invention; for section 121 protection, it must result from an Office restriction. A restriction requirement directs the applicant to elect among independent or distinct inventions, while an election of species directs the applicant to select one disclosed species for examination and does not necessarily create a section 121 restriction as to every nonelected species. Consonance means preserving the examiner’s line of demarcation among restricted inventions throughout the family. A terminal disclaimer may overcome an obviousness-type double-patenting rejection by disclaiming patent term and imposing common-ownership or enforcement conditions. Both continuations and divisionals may seek section 120 benefit, but only qualifying restriction-generated divisionals may receive section 121’s safe harbor. China permits applicant-initiated and examiner-driven divisionals, but no general U.S.-style continuation vehicle.

The United States: Priority Under Section 120 and Protection Under Section 121 Are Different Things

 

Two statutory provisions govern much of the analysis, but they do different work. Section 120 determines whether a later application may receive the benefit of an earlier U.S. filing date. Section 121 can, in narrower circumstances, prevent patents created by a restriction requirement from being used against one another in an obviousness-type double-patenting analysis. A later application may satisfy section 120 and still receive no protection under section 121.

Section 120 Preserves Priority Through a Properly Supported, Copending Chain

 

Section 120 permits a later application to obtain the filing-date benefit of an earlier application when the earlier application discloses the later-claimed invention in the manner required by section 112(a), the applications have the required inventor relationship, the later application is filed while the earlier application—or another application similarly entitled to the benefit—remains pending, and the later application contains the required specific reference to the earlier application. 35 U.S.C. §§ 112(a), 120 (2018); 37 C.F.R. § 1.78(d)(1)–(3) (2025).

The central point for the hypothetical is that section 120 asks whether the earlier application disclosed the later-claimed invention, not whether it previously claimed that invention. Thus, if the original specification provides adequate written-description and enablement support for D, E, and F, a continuation may claim those inventions even though the original claim set addressed only A, B, and C. The absence of original claims to D through F is important to section 121, discussed below, but it is not by itself fatal under section 120.

Copendency must exist through the relevant chain. A continuation filed while the original application is pending can preserve a route back to the original filing date. A later application can then rely on that continuation if the statutory requirements remain satisfied. The Federal Circuit has held that a continuation filed on the same day that its parent patent issues satisfies section 120’s timing requirement because the parent remains pending at least until issuance that day. Immersion Corp. v. HTC Corp., 826 F.3d 1357, 1363–65 (Fed. Cir. 2016). That holding is useful when an emergency arises, but deliberate practice should not depend on same-day filing. Filing before the issue date—and preferably before paying the issue fee when the family strategy has not been completed—avoids needless timing and processing risk.

Every link also needs a legally sufficient benefit claim. The benefit claim should identify each relevant prior application in the application data sheet in compliance with Rule 1.78. A passing reference in the specification does not necessarily cure a defective benefit claim. See Droplets, Inc. v. E*TRADE Bank, 887 F.3d 1309, 1316–18 (Fed. Cir. 2018). The claimed subject matter must also be supported throughout the relied-upon chain. A shared title, copied specification, or common benefit paragraph cannot substitute for actual support under section 112(a). Regents of the University of Minnesota v. Gilead Sciences, Inc., 61 F.4th 1350, 1356–60 (Fed. Cir. 2023).

The practical consequence is that “keeping an application pending” is not a free-standing legal doctrine. It is shorthand for maintaining a chain in which copendency, disclosure, inventorship, and specific references all remain intact. If a critical link is abandoned without a timely successor, a later filing cannot recreate the lost chain merely by referring to the original application.

Section 121 Is a Narrow Safe Harbor Created by an Examiner’s Restriction Requirement

 

Section 121 addresses a different problem. When the United States Patent and Trademark Office requires an applicant to divide independent and distinct inventions, the applicant should not ordinarily suffer a double-patenting penalty for complying with that requirement. The statute therefore provides that, when its conditions are met, a patent issuing from the restricted application or a resulting divisional will not be used as a reference against the original application, the divisional application, or patents issuing from them. 35 U.S.C. § 121 (2018).

The safe harbor is exacting. There must be a sufficiently documented restriction requirement. The subject matter for which protection is sought must have been formally claimed and divided in response to that requirement; disclosure standing alone is not enough. Geneva Pharms., Inc. v. GlaxoSmithKline PLC, 349 F.3d 1373, 1381–82 (Fed. Cir. 2003). The relevant branch must originate in a true divisional filed as a result of the restriction. The Federal Circuit has repeatedly declined to extend the statutory protection to a continuation-in-part merely because it descends from a restricted application. Pfizer, Inc. v. Teva Pharms. USA, Inc., 518 F.3d 1353, 1360–62 (Fed. Cir. 2008). Nor can a patent owner ordinarily convert an application into a protected divisional years later simply by relabeling it during reissue or reexamination. See G.D. Searle LLC v. Lupin Pharms., Inc., 790 F.3d 1349, 1354–55 (Fed. Cir. 2015); In re Janssen Biotech, Inc., 880 F.3d 1315, 1322–23 (Fed. Cir. 2018).

The applications must also maintain “consonance” with the examiner’s restriction. In practical terms, the claim groupings in the family must continue to respect the line of demarcation the examiner drew among the restricted inventions. Combining claims from opposite sides of that line, or shifting the line during later prosecution, may forfeit the safe harbor. St. Jude Med., Cardiology Division, Inc. v. Access Closure, Inc., 729 F.3d 1369, 1379–81 (Fed. Cir. 2013); Geneva Pharmaceuticals, 349 F.3d at 1381–82.

Section 121 expressly includes a timing condition: the divisional must be filed before a patent issues on the other application. The Federal Circuit permits section 121 protection to extend through a divisional-of-a-divisional lineage, and in some circumstances through a continuation descending from a proper divisional. Boehringer Ingelheim International GmbH v. Barr Laboratories, Inc., 592 F.3d 1340, 1352–54 (Fed. Cir. 2010); Amgen Inc. v. F. Hoffmann-La Roche Ltd., 580 F.3d 1340, 1353–54 (Fed. Cir. 2009). Those cases, however, should not be treated as an invitation to postpone the creation of a commercially important restricted branch until after the original patent issues. A later application may retain section 120 priority through an intermediate application while presenting a serious question whether section 121 protects it against an already-issued patent. The conservative course is to file each important divisional branch before the first patent in the restricted family issues.

Applying U.S. Law to the A–F Hypothetical

 

B and C Should Ordinarily Be Filed as Separate Divisionals

 

B and C present the clearest case for divisional treatment. They were claimed in the original application, the examiner formally restricted them from elected invention A, and the applicant withdrew their claims in response. Assuming the restriction remains in force and the later claims preserve the examiner’s lines of demarcation, applications directed to B and C can qualify as divisionals under sections 120 and 121.

For the strongest safe-harbor position, the applicant should file a B divisional and a C divisional while the A application is still pending and before the A patent issues. Filing both branches directly from the original application creates the cleanest record. Section 121 does not invariably require every nonelected group to be placed in a separate application; two nonelected inventions may be prosecuted together without necessarily losing consonance. Boehringer, 592 F.3d at 1350–54. A combined B/C application may nevertheless draw a new restriction, complicate the family architecture, and force a later decision about C after the A patent has issued. Separate direct divisionals are usually worth the added filing cost when both inventions are commercially meaningful and maximum section 121 protection matters.

The issue-fee deadline is not itself the statutory divisional deadline. The operative concern is patent issuance. Nevertheless, waiting until after issue-fee payment compresses the available time, increases the risk that an issuance event will overtake the filing plan, and can complicate correction of clerical errors. The better docketing practice is to decide on all restricted branches before paying the issue fee and to file any desired divisionals promptly.

It is possible to file B first and later file C as a divisional of B. Boehringer confirms that a divisional of a divisional is not categorically outside section 121. 592 F.3d at 1352–54. But if C is not filed until after the A patent has issued, section 120 priority and section 121 immunity become separate questions. C may still have a valid priority chain through B, yet its safe-harbor position against A may be disputed because C itself did not exist before A issued. Filing the direct B and C divisionals before issuance avoids that unnecessary issue.

A3 Is Ordinarily Continuation Subject Matter, Not Restricted Divisional Subject Matter

 

The stated restriction separated A, B, and C. It did not divide A1, A2, and A3. If A3 was merely disclosed but not separately identified in an election-of-species or restriction requirement, a later application directed to A3 ordinarily should be filed as a continuation under section 120. The fact that the allowed claims ultimately cover only A1 and A2 does not transform A3 into a nonelected invention protected by section 121.

That distinction matters. A continuation directed to A3 can receive the original filing date if the original disclosure supports the new claims and the continuation is timely filed. But the A3 branch ordinarily will not receive section 121’s protection from an obviousness-type double-patenting rejection based on the A1/A2 patent. If A3 is an obvious variation of the issued claims, the applicant may need to establish patentable distinctness or file a terminal disclaimer, with the accompanying common-ownership, common-enforcement, patent-term, and patent-term-adjustment consequences.

The result may change if the prosecution history contains a separate, formal election-of-species or restriction requirement that identifies A1, A2, and A3 as distinct species or inventions and A3 was withdrawn in response. In that event, an A3 divisional may be appropriate, and section 121 may be available if all statutory requirements and the consonance requirement are satisfied. The label should follow the actual record. An allowance limited to A1 and A2, standing alone, is not the equivalent of a restriction against A3.

D Through F May Be Claimed in a Continuation Even Though They Were Never Claimed Before

 

Section 120 does not require D, E, or F to have appeared in the original claims. If the original application describes each invention with adequate written-description and enablement support, a continuation filed during the required pendency may present claims to D, E, or F and seek the original filing date. The USPTO may later impose a restriction among those inventions, but their absence from the first claim set does not disqualify them from continuation practice.

Those applications do not receive section 121 protection based on the A/B/C restriction, however. The examiner did not restrict D, E, or F, and the original application did not contain entered claims to those inventions. Calling a D–F application a “divisional” does not supply the missing predicate. See Geneva Pharmaceuticals, 349 F.3d at 1381–82. The safer characterization is a continuation unless and until a later restriction requirement creates a proper divisional path.

Whether D, E, and F should be placed in one continuation is a business and unity question. A single continuation may be economical as an initial filing, but it may immediately draw another restriction requirement. If each invention has independent commercial value, the applicant should consider separate continuations or at least ensure that a successor is filed before the shared application terminates. The substantive support for each claim should be mapped to the original disclosure before filing; a generic statement that all embodiments may be combined will not always satisfy section 112(a).

A3 Can Potentially Be Filed Through a Pending D–F Application, but That Is Usually Not the Cleanest Route

 

Suppose the applicant timely files a continuation directed to D through F while the original A application is pending. The A patent then issues, but the D–F continuation remains pending. Could the applicant later file an A3 continuation from the D–F application?

Potentially, yes. Section 120 permits reliance on an “application similarly entitled” to the benefit of the first application. If the D–F continuation was timely filed, repeats or otherwise contains adequate support for A3, has the required inventor relationship, correctly claims the original application’s benefit, and remains pending when the A3 application is filed, it can serve as the copending link. The A3 application must itself contain the correct specific references and name the proper inventor or inventors. Each link must work; the mere fact that all applications belong to the same corporate patent family is insufficient.

The route is legally possible but strategically fragile. Inventorship for D through F may not overlap appropriately with inventorship for A3. Prosecution amendments may create questions about whether the intermediate specification supports the later claims. A defective priority statement or accidental abandonment in the D–F branch could break the chain. The route also does nothing to create section 121 protection for A3, because the A/B/C restriction did not divide A3 from A1 and A2.

When A3 is already known to be important, the cleaner practice is to file a direct A3 continuation from the original application before it issues, in parallel with any D–F continuation. A cross-branch filing should be treated as a backup created by a valid pending chain, not as the preferred family architecture.

A Sensible U.S. Filing Architecture

 

Before the A patent issues, the applicant should ordinarily create separate B and C divisionals to preserve the best section 121 position. The applicant should also file a continuation directed to A3 if commercially worthwhile and one or more continuations directed to D through F if those disclosed inventions may matter. The A3 and D–F applications depend principally on section 120, not the original restriction. Keeping at least one continuation pending can preserve later flexibility for adequately disclosed subject matter, but the family should not be reduced to one generic placeholder if doing so creates avoidable support, inventorship, or safe-harbor risk.

The resulting architecture is intentionally asymmetric. The B and C branches track the examiner’s restriction and are designed to preserve consonance. The A3 and D–F branches preserve disclosed subject matter through continuation practice. Treating every child as interchangeable would obscure the different statutory reasons for filing each one.

China: Divisional Practice Without a U.S.-Style Continuation

 

China begins from a different procedural model. Chinese law permits an applicant to divide an application that contains two or more inventions, whether division is prompted by a lack-of-unity objection or undertaken voluntarily. It does not provide a direct analogue to the U.S. continuation that can remain pending as a general vehicle for later claims to any adequately disclosed subject matter.

“Voluntary” in this context means applicant-initiated; it does not mean that the applicant may keep any disclosed subject matter alive indefinitely through serial pending divisionals.

Article 31 of the Patent Law requires an invention or utility-model application to be limited to one invention, subject to the exception for two or more inventions or utility models belonging to a single general inventive concept. Article 33 prohibits amendments that extend beyond the scope of the original disclosure. Patent Law of the People’s Republic of China arts. 31, 33 (promulgated by the Standing Comm. Nat’l People’s Cong. Mar. 12, 1984, amended Oct. 17, 2020, effective June 1, 2021) (China) [hereinafter PRC Patent Law]. A Chinese divisional therefore must be grounded in subject matter disclosed in the original application and must constitute a technical solution that can properly be pursued as a separate invention. It is not merely an opportunity to begin a fresh prosecution campaign around any desired variation.

The Ordinary Chinese Divisional Deadline Is Tied to the Grant-Registration Period

 

Under current Article 48, an applicant may file a divisional before expiration of the period specified in Article 60(1). Article 60(1) generally gives the applicant two months from receipt of the notice to complete the formalities of registration following a decision to grant. Rules for the Implementation of the Patent Law of the People’s Republic of China arts. 48–49, 60 (2023 rev.) (China) (amended by State Council Decree No. 769, Dec. 11, 2023, effective Jan. 20, 2024) [hereinafter Implementing Rules]. The ordinary deadline is therefore more precise than the loose statement that a divisional must be filed “while the parent is pending” or “before grant.” It is generally the end of the two-month registration-formalities period measured from the notice of grant.

CNIPA has clarified that early completion of the registration formalities and even issuance of the patent certificate before the two-month period expires do not necessarily cut off the remaining statutory divisional period. See China Nat’l Intell. Prop. Admin., Can a Divisional Application Be Filed After the Parent Patent Certificate Has Issued? (Oct. 20, 2025). That clarification is helpful, but it should not become routine docketing policy. Filing before completing the registration formalities, and well before the two-month period ends, remains the conservative practice.

Special rules apply when the original application is rejected. The Patent Examination Guidelines permit filing a divisional during the three-month period for requesting reexamination following receipt of a rejection decision, regardless of whether reexamination is actually requested; during a reexamination proceeding; during the period for challenging an adverse reexamination decision; and during ensuing administrative litigation. By contrast, a divisional generally may not be filed from an application that has been withdrawn, deemed withdrawn without restoration, or finally rejected after the applicable periods have expired. China Nat’l Intell. Prop. Admin., Patent Examination Guidelines pt. I, ch. 1, § 5.1.1(3), CNIPA Order No. 78 (Dec. 21, 2023, effective Jan. 20, 2024) (China) [hereinafter CNIPA Guidelines].

These exceptions are important, but they are not substitutes for an affirmative filing plan. A portfolio should not depend on preserving divisional rights through rejection merely to obtain more time.

A Pending Chinese Divisional Ordinarily Does Not Restart the Voluntary-Divisional Clock

 

This is the most consequential difference from U.S. continuation practice. For an ordinary voluntary further divisional, CNIPA generally tests timeliness against the first-filed or original application, not against the pendency of the immediate divisional. If the original application’s divisional window has closed, maintaining a first-generation divisional ordinarily does not preserve a general right to carve out additional subject matter later. CNIPA Guidelines pt. I, ch. 1, § 5.1.1(3).

The CNIPA Guidelines recognize a narrow exception when an examiner expressly raises lack of unity in a pending divisional. In that circumstance, the applicant may file a further divisional responsive to the examiner’s unity objection, and timeliness may be assessed with reference to the pending divisional. The exception is tied to the subject matter actually divided by the examiner. It is not a general reopening of the original disclosure. If an examiner concludes that D, E, and F lack unity in a D–F divisional, the exception may support further division among D, E, and F. It does not ordinarily revive a lapsed opportunity to pursue unrelated A3. See China Nat’l Intell. Prop. Admin., Explanation of the 2019 Amendments to the Patent Examination Guidelines pt. III(A)(1) (Oct. 30, 2019) (China); China Nat’l Intell. Prop. Admin., Announcement on Amending the Patent Examination Guidelines, Announcement No. 328, pt. I (Sept. 23, 2019, effective Nov. 1, 2019) (China).

Accordingly, a Chinese D–F divisional cannot safely be used as the equivalent of a U.S. continuation bridge for a later A3 filing. Once the ordinary deadline measured from the first application has passed, A3 may be unavailable unless it falls within the particular examiner-driven further-division exception. The fact that the D–F application is still under examination does not change that result.

Formal and Substantive Requirements Also Constrain the Chinese Branches

 

A valid Chinese divisional retains the filing date of the original application and, when properly claimed, the relevant priority date. It must identify the original application, stay within the original disclosure, and remain in the same category of application; an invention application cannot be converted into a utility-model application merely through division. Implementing Rules arts. 48–49.

Priority should not be treated as automatic. Effective January 1, 2026, the Patent Examination Guidelines expressly provide that when the original application claimed priority but the applicant does not declare that priority in the divisional request, the divisional is deemed not to claim it and CNIPA will issue a notice to that effect. China Nat’l Intell. Prop. Admin., Decision on Amending the Patent Examination Guidelines § 3, CNIPA Order No. 84 (Nov. 10, 2025, effective Jan. 1, 2026) (China) [hereinafter CNIPA Order No. 84]. Although restoration may be available in appropriate circumstances, a Chinese divisional filing checklist should include an express verification of every priority claim rather than assuming that priority follows automatically from the parent number.

Inventorship can create another trap, especially for a further divisional. Chinese practice generally requires the inventor or inventors named in a divisional to be the inventor or a subset of the inventors associated with the application from which it is divided. CNIPA Guidelines pt. I, ch. 1, § 5.1.1(4). If the first D–F divisional omits the person who invented A3, attempting to derive an A3 further divisional from that branch may create an additional formal obstacle even apart from timing. The filing architecture should therefore account for which inventors contributed to each technical solution before the first generation of divisionals is submitted.

Applying Chinese Law to the A–F Hypothetical

 

B and C

 

Because B and C were claimed and separated from A, they are natural candidates for Chinese divisionals if the Chinese examiner also raises lack of unity. They may also be pursued through voluntary divisionals, assuming the disclosure and unity analysis support separate inventions. If B and C each have commercial importance, the prudent strategy is to file both before the original Chinese application’s ordinary divisional deadline. Filing B and assuming that a pending B divisional will preserve C is unsafe.

The Chinese analysis does not depend on importing the U.S. restriction record. A U.S. restriction requirement may be informative to the portfolio team, but it does not establish Chinese lack of unity or extend a Chinese deadline. Each jurisdiction applies its own law to the claims and technical relationship among the inventions.

A3

 

A3 can potentially be pursued in a voluntary Chinese divisional if the original Chinese application adequately discloses it and A3 constitutes a distinct technical solution suitable for separate protection. If A3 is merely a narrower embodiment or alternative claim scope within the same invention A, however, the applicant should not assume that China’s divisional mechanism functions like a U.S. continuation. The claims must comply with Chinese unity, support, amendment, and double-patenting rules.

If A3 is important, it should be divided directly or otherwise placed into a timely Chinese divisional before the original application’s window closes. Filing D through F and planning to extract A3 later is not a reliable strategy. An examiner’s later unity objection among D, E, and F would generally authorize further division responsive to that objection, not a return to the unrelated A branch.

D Through F

 

The fact that D, E, and F were not claimed in the first application does not necessarily prevent voluntary division in China. If they were clearly disclosed as distinct technical solutions and the divisional does not add subject matter, they may potentially be pursued in one or more timely divisionals. PRC Patent Law arts. 31, 33; Implementing Rules arts. 48–49.

The practical difference from the United States lies in timing. The applicant should decide before the original Chinese divisional window closes which of D, E, and F deserve their own filings. Grouping them in one application may be reasonable if they share a single general inventive concept, but it should not be done on the assumption that the applicant can voluntarily split them at any later time merely because that grouped divisional remains pending. Where each invention has substantial independent value, contemporaneous filings offer the more dependable preservation strategy.

Double Patenting: Section 121 and Terminal Disclaimers Have No Exact Chinese Equivalent

 

The United States and China also approach overlapping family claims differently. In the United States, statutory double patenting prevents two patents on the identical invention, while obviousness-type double patenting can bar claims that are not patentably distinct from claims in a commonly owned patent. A terminal disclaimer can often overcome the latter, subject to common ownership and enforceability requirements, but it may shorten effective patent life and affect patent-term adjustment. Section 121 can provide a safe harbor when the overlap results from the USPTO’s restriction and the applicant has preserved the statutory conditions.

China’s Article 9 provides that only one patent may be granted for the same invention-creation. PRC Patent Law art. 9. CNIPA generally treats claims as directed to the same invention-creation for this purpose when their scopes of protection are the same. Mere partial overlap ordinarily does not establish Article 9 identity, although an identical, clearly separable alternative technical solution can still trigger the rule, and the claims must satisfy novelty, inventiveness, support, unity, and other requirements. CNIPA Guidelines pt. II, ch. 3, § 6.2.

China does not offer a general terminal-disclaimer procedure comparable to U.S. practice. If parent and divisional claims are identical in scope, the usual solution is to amend or delete one set, not to disclaim the end of one patent’s term. A valid Chinese divisional shares the original filing date, so the parent’s publication ordinarily does not become earlier prior art against the divisional merely because the parent is examined or granted first. The serious danger arises when the divisional deadline is missed and the applicant files an ordinary new application. That new application does not inherit the original date, and the original family’s disclosure may then become prior art or an earlier-filed, later-published conflicting application under Article 22. PRC Patent Law art. 22.

The contrast is therefore conceptual as well as procedural. U.S. counsel often worries whether a later family patent is protected from obviousness-type double patenting and whether a terminal disclaimer is available. Chinese counsel more often must ensure that the later filing is a timely, valid divisional, that it does not claim identical scope, and that no original priority or filing-date benefit is lost through a formal or timing error.

U.S.–China Comparison at a Glance

 

The following table compresses the principal structural differences. It is a planning aid, not a substitute for reviewing the actual claim groupings and procedural record.

Issue	United States	China
General later-claim vehicle	Continuation for supported subject matter; divisional for a carved-out invention	Voluntary or examiner-driven divisional; no direct U.S.-style continuation
A3 on the stated facts	Ordinarily a continuation unless separately restricted	Potential voluntary divisional only if A3 is a distinct technical solution
D–F, never originally claimed	May be claimed in a continuation if § 112(a) support and continuity requirements are met	May be divided if adequately disclosed as distinct technical solutions and filed on time
Ordinary timing principle	Continuous copendency; file restricted branches before issuance for the strongest § 121 position	Original application’s two-month grant-registration period under Implementing Rules arts. 48, 60(1)
Effect of a pending intermediate case	A qualifying intermediate application can preserve § 120 benefit	A pending divisional ordinarily does not restart the voluntary-divisional clock
Further division	Serial continuations and divisionals may be available if each link satisfies the governing rules	Normally tied to the original deadline; narrow exception for examiner-found nonunity in the divisional
Family double-patenting framework	Obviousness-type double patenting, terminal disclaimers, and a narrow § 121 safe harbor	Article 9 bars identical invention-creations; no general terminal-disclaimer counterpart

Coordinating a Parallel U.S.–China Strategy

 

For the U.S. family, the applicant should use the original restriction to establish clean, separate B and C divisional branches before the A patent issues. A3 should ordinarily be placed in a continuation unless the record contains a specific restriction or species election covering it. D through F can be pursued in one or more continuations if the original disclosure supplies section 112(a) support. A pending continuation can preserve later U.S. options, including in some circumstances a route from a D–F application to A3, but each priority-chain and inventorship requirement must remain satisfied.

For the Chinese family, the applicant should work backward from the original application’s two-month grant-registration deadline and identify every commercially important technical solution before that window closes. B, C, A3, and D through F should be divided directly or organized into carefully justified groups while timely. Grouping should be based on unity and commercial logic, not on an assumption that a pending first-generation divisional will preserve a later voluntary right to split any remaining disclosure.

The two filing calendars should therefore be linked but not mirrored. The same specification and business priorities can inform both plans, but U.S. procedural labels should not be copied into the Chinese docket. A U.S. “continuation placeholder” has no reliable Chinese equivalent, and a Chinese voluntary divisional does not acquire the U.S. section 121 safe harbor merely because it is called a divisional.

Recurring Traps

 

Confusing Priority With the Section 121 Safe Harbor

 

A later U.S. application can receive the original filing date under section 120 while remaining fully exposed to obviousness-type double patenting. D through F illustrate the point: disclosure may establish priority, but the A/B/C restriction does not protect inventions the examiner never restricted. The same is ordinarily true for A3 on the stated facts.

Treating Disclosure as Though It Were a Restricted Claim

 

Section 121 requires more than a specification that mentions an invention. The original application must have contained claims to the subject matter, and the examiner must have required division with sufficient clarity to establish the relevant boundaries. Geneva Pharmaceuticals, 349 F.3d at 1381–82. This is why B and C stand differently from D through F.

Crossing the Examiner’s Restriction Lines

 

Consonance can be lost when claims from separately restricted groups are recombined in the same lineage. A family map should preserve the examiner’s exact groupings, including later withdrawals, rejoinders, and revised restrictions. The application title and relationship paragraph are less important than the substance of the claims and the prosecution record.

Assuming One Pending Application Preserves Everything Everywhere

 

The statement is incomplete even in the United States, because support, copendency, specific references, and inventorship still matter. It is affirmatively dangerous in China, where a pending divisional ordinarily does not restart the voluntary-divisional deadline measured from the original application.

Relying on a Chinese Further Divisional to Reach Unrelated Subject Matter

 

The examiner-driven further-divisional exception is narrow. A lack-of-unity objection in a D–F divisional may preserve an opportunity to separate D, E, and F. It generally does not reopen A3. The proposed further divisional should correspond closely to the technical solutions identified in the examiner’s objection.

Neglecting Formal Priority and Inventorship Checks

 

U.S. benefit claims should be verified in the application data sheet at every generation. Chinese priority must now be expressly declared in the divisional request. See CNIPA Order No. 84, § 3. Inventorship should also be mapped by invention before branch applications are filed, especially where a later U.S. cross-branch continuation or Chinese further divisional is contemplated.

Conclusion

 

The A–F hypothetical reveals why “file a continuation” or “file a divisional” is not a complete answer. In the United States, B and C should ordinarily be pursued in separate divisionals filed before the A patent issues because they arose from the examiner’s restriction. A3 ordinarily belongs in a continuation, unless a separate restriction or species election placed it on the nonelected side of an Office-imposed line. D through F may be claimed in a continuation despite never appearing in the original claims, provided the original disclosure and the section 120 chain support them. A3 may potentially be reached through a pending D–F continuation, but a direct continuation is cleaner and less vulnerable to chain and inventorship problems.

China requires earlier and more comprehensive decisions. B, C, A3, and D through F may potentially be pursued as voluntary or examiner-driven divisionals if they are adequately disclosed and constitute proper separate technical solutions, but the ordinary filing deadline remains tied to the first application’s grant-registration period. A pending divisional usually does not preserve a general right to divide again, and an examiner’s unity objection in that divisional creates only a subject-matter-specific exception.

For a coordinated portfolio, the safest approach is deliberate asymmetry. Use U.S. continuation practice to maintain a supported pending chain, while creating the restricted B and C branches early enough to preserve section 121. In China, identify and file every important voluntary branch before the original divisional window closes. The specification may be the same, but the procedural architecture should reflect the law of each jurisdiction.

This article provides general information and does not constitute legal advice. Filing strategy depends on the actual disclosure, claims, restriction or unity record, inventorship, priority documents, procedural posture, and current law in each jurisdiction.